Introduction: The DSM-5 Alternative Model of Personality Disorders (AMPD) and the ICD-11 classification of personality disorders (PD) are largely commensurate and, when combined, they delineate 6 trait domains: negative affectivity, detachment, antagonism/dissociality, disinhibition, anankastia, and psychoticism. Objective: The present study evaluated the international validity of a brief 36-item patientreport measure that portrays all 6 domains simultaneously including 18 primary subfacets. Methods: We developed and employed a modified version of the Personality Inventory for DSM-5-Brief Form Plus (PID5BF+). A total of 16,327 individuals were included, 2,347 of whom were patients. The expected 6-factor structure of facets was initially investigated in samples from Denmark (n = 584), Germany (n = 1,271), and the USA (n = 605) and subsequently replicated in both patient-and community samples from Italy,
According to Young's schema model (Young, J. E., Klosko, J. S., & Weishaar, M. E. (2003). Schema therapy: A practitioner's guide. New York: Guilford Press), innate personality tendencies are important for the understanding of early maladaptive schemas (EMS). The current study examined the relations between EMS and the dimensions of the five-factor model of personality (FFM). One hundred and forty-seven adult outpatients completed the NEO PI-R, the Schema Questionnaire-Short Form (SQ-SF), and the Beck Depression Inventory (BDI). Correlational analyses showed a substantial overlap between EMS and the FFM, neuroticism in particular. EMS predicted depressive symptoms above and beyond the FFM personality dimensions. Implications of these findings are discussed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.